Triamcinolone acetonide and Lucentis drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Triamcinolone acetonide (triamcinolone acetonide) and Lucentis (ranibizumab). Common drug interactions include visual acuity reduced among females and visual acuity reduced among males.

The phase IV clinical study analyzes what interactions people have when they take Triamcinolone acetonide and Lucentis. It is created by eHealthMe based on reports of 66 people who take the same drugs from the FDA, and is updated regularly.

What is Triamcinolone acetonide?

Triamcinolone acetonide has active ingredients of triamcinolone acetonide. It is often used in eczema. eHealthMe is studying from 19,594 Triamcinolone acetonide users. Check the latest studies of Triamcinolone acetonide.

What is Lucentis?

Lucentis has active ingredients of ranibizumab. It is often used in macular degeneration. eHealthMe is studying from 25,647 Lucentis users. Check the latest studies of Lucentis.

On Jul, 26, 2026

66 people who take Triamcinolone acetonide and Lucentis together, and have interactions are studied.

Triamcinolone acetonide and Lucentis drug interactions.

What are the common drug interactions of Triamcinolone Acetonide and Lucentis, by gender? *:

female:

Visual acuity reduced (reduced clearness of vision)
Vision blurred
Detachment of retinal pigment epithelium
Polypoidal choroidal vasculopathy (polyp-like sub-retinal pigment epithelium vascular abnormalities predominantly found in the macula and peripapillary region)
Vitreous floaters (spots before the eyes)
Age-related macular degeneration
Anterior chamber inflammation
Retinal depigmentation (change in colour of retina)
Blood glucose increased
Cystoid macular oedema (fluid accumulation after cataract surgery)

male:

Visual acuity reduced (reduced clearness of vision)
Diabetic retinal oedema (excessive build-up of fluid in the retina due to diabetes)
Macular oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken)
Retinal pigment epithelial tear (pigment epithelial tear of retina)
Subretinal fibrosis (formation of excess fibrous connective tissue in subretinal)
Diabetic retinopathy (damage to the retina caused by complications of diabetes)
Vitreous opacities (vitreous opacities generally develop as aging changes within the eye)
Abasia (inability to walk)
Eye swelling
Eyelid oedema (eyelids are swollen and contain excessive fluid)

What are the common drug interactions of Triamcinolone Acetonide and Lucentis, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Drug resistance (reduction in effectiveness of a drug)
Macular oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken)

50-59:

Vision blurred
Visual acuity reduced (reduced clearness of vision)
Blood glucose increased
Cystoid macular oedema (fluid accumulation after cataract surgery)
Hypermetropia (abnormal condition in which vision for distant objects is better than for near objects)
Intraocular pressure increased
Macular fibrosis (a thin sheet of scar tissue forms on top of the macula, in response to damage or injury)
Skin candida (fungal infection of skin)
Upper limb fracture
Vitreous haemorrhage (intraocular (inside the eye) bleeding)

60+:

Visual acuity reduced (reduced clearness of vision)
Diabetic retinal oedema (excessive build-up of fluid in the retina due to diabetes)
Retinal depigmentation (change in colour of retina)
Retinal artery occlusion (blockage of retinal artery)
Intraocular pressure increased
Retinal pigment epithelial tear (pigment epithelial tear of retina)
Subretinal fibrosis (formation of excess fibrous connective tissue in subretinal)
Cerebral infarction (less blood supply to brain resulting tissue damage)
Choroidal neovascularisation (creation of new blood vessels in vascular layer of eye)
Diabetic retinopathy (damage to the retina caused by complications of diabetes)

What are the existing conditions these people have? *

Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 22 people, 33.33%
Age-Related Macular Degeneration: 19 people, 28.79%
Polypoidal Choroidal Vasculopathy (polyp-like sub-retinal pigment epithelium vascular abnormalities predominantly found in the macula and peripapillary region): 9 people, 13.64%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 7 people, 10.61%
Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 6 people, 9.09%
Choroidal Neovascularisation (creation of new blood vessels in vascular layer of eye): 5 people, 7.58%
Type 2 Diabetes: 4 people, 6.06%

* Approximation only. Some reports may have incomplete information.

Do you take Triamcinolone acetonide and Lucentis?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously